Bergamottin a bioactive compound unveiled: exploring its potential in disease managments and in-silico insights

Abstract

Bergamottin (BGM), major furanocoumarins present in citrus fruits such as grapefruit. BGM is found in both the skin and flesh of grapefruit and has been reported in flavedo at concentrations as high as 666.54 μg g⁻¹ dry weight.BGM has been reported to induce elevated bioavailability of drugs via the inhibition of multiple cytochrome P450 enzymes, such as CYPs3A4. The present review will focus on anti-cancer, ant-inflammatory, anti-obesity potential of bergamottin through literature review and in silico study. Thorough literature search was carried out utilizing specialized and dedicated search platforms.In different types of cancer BGM has anticancer effect. NF-κB inhibition by BGM is a desirable way to manage inflammation.In diabetes treatment, it increased glucose uptake by 41.6% after a 24-h period. In obese patients, BGM affected the expression of adipogenic factors during 3T3-L1 differentiation and ampK signalling activation.Role of bioactive compound against inflammation, cancer and diabetes analyzed through network pharmacology (ADME, Networking and Docking). Gene ontology and Kegg analysis showed BGM is effective through dfferent cancer and immune system pathways. Docking analysis performed by receptor protein 6Y3C (Human COX-1) and 6DWM that have best fit with the compound: Bergamottin having docking scores of −8.46 and −11.1 respectively. In conclusion, BGM can be characterized as novel compound in drug development.